Zhou Q - Search Results

1

Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models.

Zhang X, Lv H, Zhou Q, Elkholi R, Chipuk JE, Reddy MV, Reddy EP, Gallo JM. Zhang X, et al. Among authors: zhou q. Mol Cancer Ther. 2014 May;13(5):1105-16. doi: 10.1158/1535-7163.MCT-13-0847. Epub 2014 Feb 25. Mol Cancer Ther. 2014. PMID: 24568969 Free PMC article.

2

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.

Wang S, Guo P, Wang X, Zhou Q, Gallo JM. Wang S, et al. Among authors: zhou q. Mol Cancer Ther. 2008 Feb;7(2):407-17. doi: 10.1158/1535-7163.MCT-07-2070. Mol Cancer Ther. 2008. PMID: 18281523

3

Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.

Wang S, Zhou Q, Gallo JM. Wang S, et al. Among authors: zhou q. Mol Cancer Ther. 2009 Jun;8(6):1438-47. doi: 10.1158/1535-7163.MCT-09-0089. Epub 2009 Jun 9. Mol Cancer Ther. 2009. PMID: 19509243 Free PMC article.

4

Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues.

Lv H, Wang F, Reddy MV, Zhou Q, Zhang X, Reddy EP, Gallo JM. Lv H, et al. Among authors: zhou q. Invest New Drugs. 2012 Dec;30(6):2263-73. doi: 10.1007/s10637-012-9806-x. Epub 2012 Mar 1. Invest New Drugs. 2012. PMID: 22383114 Free PMC article.

5

Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy.

Nuthalapati S, Zhou Q, Guo P, Lv H, Cosenza S, Reddy MV, Reddy EP, Gallo JM. Nuthalapati S, et al. Among authors: zhou q. Pharm Res. 2012 Sep;29(9):2499-511. doi: 10.1007/s11095-012-0780-y. Epub 2012 Jun 8. Pharm Res. 2012. PMID: 22678771

6

Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors.

Ballesta A, Zhou Q, Zhang X, Lv H, Gallo JM. Ballesta A, et al. Among authors: zhou q. CPT Pharmacometrics Syst Pharmacol. 2014 Apr 30;3(4):e112. doi: 10.1038/psp.2014.9. CPT Pharmacometrics Syst Pharmacol. 2014. PMID: 24785551 Free PMC article.

7

In vivo microdialysis for PK and PD studies of anticancer drugs.

Zhou Q, Gallo JM. Zhou Q, et al. AAPS J. 2005 Oct 24;7(3):E659-67. doi: 10.1208/aapsj070366. AAPS J. 2005. PMID: 16353942 Free PMC article. Review.

8

Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.

Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM. Zhou Q, et al. J Pharmacol Exp Ther. 2007 Apr;321(1):265-75. doi: 10.1124/jpet.106.118265. Epub 2007 Jan 26. J Pharmacol Exp Ther. 2007. PMID: 17259446

9

Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.

Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM. Zhou Q, et al. Clin Cancer Res. 2007 Jul 15;13(14):4271-9. doi: 10.1158/1078-0432.CCR-07-0658. Clin Cancer Res. 2007. PMID: 17634557

10

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.

Zhou Q, Guo P, Gallo JM. Zhou Q, et al. Clin Cancer Res. 2008 Mar 1;14(5):1540-9. doi: 10.1158/1078-0432.CCR-07-4544. Clin Cancer Res. 2008. PMID: 18316579

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22,407 results

Search Page

Filters